Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients

Roselie Achten; Judith Thijs; Chantal van Luijk; Edward Knol; Eveline Delemarre; Marlies de Graaf; Daphne Bakker; Joke de Boer; Femke van Wijk; Marjolein de Bruin-Weller

doi:10.1111/cea.14269

Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients

Roselie Achten, Judith Thijs, Chantal van Luijk, Edward Knol, Eveline Delemarre, Marlies de Graaf, Daphne Bakker, Joke de Boer, Femke van Wijk, Marjolein de Bruin-Weller

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

27 Downloads (Pure)

Original language	English
Pages (from-to)	239-243
Number of pages	5
Journal	Clinical and Experimental Allergy
Volume	53
Issue number	2
Early online date	22 Dec 2022
DOIs	https://doi.org/10.1111/cea.14269
Publication status	Published - Feb 2023

Access to Document

10.1111/cea.14269Licence: CC BY-NC-ND

Clin Experimental Allergy - 2022 - Achten - Biomarkers in tear fluid of dupilumab‐treated moderate‐to‐severe atopicFinal published version, 1 MBLicence: CC BY-NC-ND

Cite this

@article{0586c60c34bf4e6a82c2f9132d1263e4,

title = "Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients",

author = "Roselie Achten and Judith Thijs and {van Luijk}, Chantal and Edward Knol and Eveline Delemarre and {de Graaf}, Marlies and Daphne Bakker and {de Boer}, Joke and {van Wijk}, Femke and {de Bruin-Weller}, Marjolein",

note = "Funding Information: This investigated initiated study was sponsored by Sanofi Genzyme. The sponsor was not involved in the analyses, interpretation of the data and preparation of the manuscript. ",

year = "2023",

month = feb,

doi = "10.1111/cea.14269",

language = "English",

volume = "53",

pages = "239--243",

journal = "Clinical and Experimental Allergy",

issn = "0954-7894",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients

AU - Achten, Roselie

AU - Thijs, Judith

AU - van Luijk, Chantal

AU - Knol, Edward

AU - Delemarre, Eveline

AU - de Graaf, Marlies

AU - Bakker, Daphne

AU - de Boer, Joke

AU - van Wijk, Femke

AU - de Bruin-Weller, Marjolein

N1 - Funding Information: This investigated initiated study was sponsored by Sanofi Genzyme. The sponsor was not involved in the analyses, interpretation of the data and preparation of the manuscript.

PY - 2023/2

Y1 - 2023/2

UR - http://www.scopus.com/inward/record.url?scp=85145091129&partnerID=8YFLogxK

U2 - 10.1111/cea.14269

DO - 10.1111/cea.14269

M3 - Comment/Letter to the editor

C2 - 36550628

SN - 0954-7894

VL - 53

SP - 239

EP - 243

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

IS - 2

ER -

Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients

Access to Document

Other files and links

Cite this